News for Viva Biotech Holdings (1873.HK)

SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ('Langhua Pharmaceutical'), a wholly-owned subsidiary of Viva Biotech Holdings ('Viva Biotech'), underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration ('FDA'), and received the EIR (Establishment Inspection Report) from the FDA. This is the fourth time that Langhua Pharmaceutical has undergone and passed the on-site inspection by the FDA, indicating the effective operation of the Company's quality control system. It also enables the Company to offer globally customized research, development, and production services to pharmaceutical enterprises worldwide.

HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ('Viva Biotech') announced the official establishment of its new branch in Boston, USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the company's global expansion strategy. Viva Biotech aims to further enhance and deepen international collaboration networks, providing comprehensive one-stop CRO-CMC/CDMO services-from drug discovery and preclinical development to commercial manufacturing-for clients worldwide.

SHANGHAI, July 1, 2024 /PRNewswire/ -- Noah Holdings Limited ('Noah' or the 'Company') (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for Mandarin-speaking high-net-worth investors, today announced changes to its Board of Directors (the 'Board').

HONG KONG, March 28, 2024 /PRNewswire/ -- Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 millionGross profit amounted to RMB738.5 millionAdjusted non-IFRS net...

/PRNewswire/ -- On August 29, 2023, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that during the...

/PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of...

/PRNewswire/ -- DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid...

Key Takeaways： As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026 A sinking share price has piled pressure on the company to buy back its convertible bonds, hence the need for funds By Molly Wen

As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026.

HONG KONG, June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly... | June 16, 2023

/PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business,...

/PRNewswire/ -- The "Global Drug Discovery Services Market by Process (Target Selection, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small Molecule,...